Physician profile
John Koryakos
NPI 1598841884
$6,192.49
in general payments reported to CMS, 2019-2025
26 companies · $656 in 2025
The $656 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,502 · 2020: $649 · 2021: $795 · 2022: $1,128 · 2023: $742 · 2024: $721 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,119.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,163.78 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $920.67 | 2020-2025 | |
| Novo Nordisk INC | $663.22 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $448.93 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $433.28 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $400.22 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $377.56 | 2022 | |
| Pfizer INC. | $377.41 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $287.11 | 2020-2025 | Trulance, Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $266.05 | 2022 | |
| Sanofi-Aventis U.S. LLC | $158.93 | 2019-2023 | |
| Allergan, INC. | $149.21 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $139.51 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $72.13 | 2022 | |
| Gilead Sciences, INC. | $54.57 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $41.73 | 2022-2023 | |
| Amgen INC. | $36.20 | 2023-2024 | Repatha, Otezla |
| Hikma Pharmaceuticals USA | $35.14 | 2020-2021 | |
| Ethicon US, LLC | $33.42 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $25.60 | 2024 | Rexulti |
| Exact Sciences Corporation | $24.43 | 2025 | Cologuard Collection Kit |
| Eyevance Pharmaceuticals LLC | $21.21 | 2021 | |
| Nevro Corp. | $20.21 | 2021 | |
| Merck Sharp & Dohme LLC | $15.89 | 2019 | |
| Boston Scientific Corporation | $13.22 | 2023 | Superion Indirect Decompression System |
| Janssen Pharmaceuticals, INC | $12.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Koryakos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.